United Therapeutics (UTHR) Other Accumulated Expenses (2009 - 2026)

United Therapeutics has reported Other Accumulated Expenses for 18 years, with the latest figure at $100.8 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 34.76% year-over-year to $100.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.8 million (down 34.76% YoY) and the FY2025 annual result came in at $72.6 million, down 22.44% from the prior year.
• Other Accumulated Expenses rose to $100.8 million in Q1 2026 per UTHR's latest filing, from $72.6 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $154.5 million in Q1 2025 and troughed at $32.5 million in Q4 2022.
• A 5-year average of $74.4 million and a median of $72.6 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses plunged 36.51% in 2023, then soared 227.2% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $32.5 million in 2022, then jumped by 118.46% to $71.0 million in 2023, then jumped by 31.83% to $93.6 million in 2024, then decreased by 22.44% to $72.6 million in 2025, then jumped by 38.84% to $100.8 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $100.8 million, $72.6 million, and $78.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.